TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22781292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rh‐Endostatin with neoadjuvant DE regimen
Study: 20044128
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus pegylated liposomal doxorubicin (PLD) (30 mg/m(2))
Study: 20044128
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent carboplatin (AUC 5)
Study: 20044128
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus PLD (30 mg/m(2))
Study: 20552173
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (7 mg/24 h)
Study: 15883442
Drug: Vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin therapy (0.5 mg cyanocobalamin, 0.8 mg folic acid, 3 mg vitamin B‐6)
Study: 12823149
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) 5 mg/day o.d.
Study: 12823149
Drug: 5-ASA 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA 0.8 g t.d.s.
Study: 11938806
Drug: Supplementary moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary moxibustion on Shenque (Ren 8) point during radio- and chemotherapy (30 sessions).
Study: 11938806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (radio- and chemotherapy without moxibustion).
Study: 8796367
Drug: Cyproheptadine 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine 16 mg day-1
Study: 27760089
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris 750 mg/d for 120 days
Study: 25456571
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus prize-based contingency management (CBT + prizeCM)
Study: 16193589
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 mg/ml)‐epinephrine (5 microg/ml) infiltration
Study: 12943623
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy alone (Group A, n=23)
Study: 12943623
Drug: Postoperative radio/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative radio/chemotherapy (Group B, n=22)
Study: 12943623
Drug: Postoperative radio/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative radio/chemotherapy (Group B)
Study: 12943623
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy alone (Group A)
Study: 6376299
Drug: Benzopyrone drug
Normalized name: benzopyrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzopyrone drug (verum group)
Study: 29133522
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group in SPRINT
Study: 29133522
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group in SPRINT
Study: 29133522
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group in ACCORD
Study: 29133522
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group in ACCORD
Study: 23504807
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (8 mg/kg)
Study: 23504807
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (6 mg/kg)
Study: 16340190
Drug: Azithromycin (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (4.5 g total dose, 1 x 500 mg weekly for 3 weeks)
Study: 16340190
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg b.i.d. for 21 days)
Study: 10707787
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous unpurged stem-cell transplantation (U)
Study: 10707787
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous purged stem-cell transplantation (P)
Study: 10707787
Drug: Chemotherapy control
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy control group (C)
Study: 30829023
Drug: Verteporfin-photodynamic therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin-photodynamic therapy (standard and low-dose/low-fluence protocols)
Study: 30829023
Drug: Glucocorticoid antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glucocorticoid antagonists
Study: 22932122
Drug: Lixivaptan (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixivaptan (25-100 mg per day, titrated based on daily serum sodium measurements)
Study: 11980120
Drug: Drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and laser radiation (study group)
Study: 17393617
Drug: Drugs only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs only (control group)
Study: 9861118
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine injected at 0.02 ml s‐1 (group slow, n = 30)
Study: 9861118
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine injected at 0.25 ml s‐1 (group fast, n = 30)
Study: 7896945
Drug: Hyposensitization procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hyposensitization procedure (UVB treatment and subcutaneous nickel sulfate administration)
Study: 7896945
Drug: Control (UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (UVB treatment only)
Study: 2631476
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg gallopamil (G)
Study: 2631476
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg propranolol (P)
Study: 2631476
Drug: 0.12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg Atenolol (A)
Study: 320919
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol (800 g daily for 12 weeks)
Study: 26021829
Drug: DPP4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitor (gemigliptin)
Study: 9486387
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Hib vaccine
Study: 9486387
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Hib vaccine
Study: 8106775
Drug: Parenteral trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral trivalent inactivated influenza vaccine containing either influenza B/Ann Arbor/86 or B/Yamagata/88 hemagglutinin antigens
Study: 2633018
Drug: Heavy bupivacaine
Normalized name: bupivacaine hydrochloride Injectable Solution [Marcain Heavy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy bupivacaine 12 mg
Study: 2633018
Drug: Tetracaine 12
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracaine 12 mg in 2.5 mL of 10% dextrose
Study: 56898
Drug: 2.5% Oxypolygelatine-solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% Oxypolygelatine-solution
Study: 56898
Drug: 4.5% Dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5% Dextran 60 solution
Study: 56898
Drug: 6% Hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethyl starch solution
Study: 31707618
Drug: B&L SuperEndo
Approvals — FDA: no, EMA: no, PMDA: no
Description: B&L SuperEndo Alpha II unit
Study: 26009916
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of a provisional crown after sinus elevation bone grafting at the time of implant placement (G2)
Study: 26009916
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of a provisional crown with no bone augmentation (G3)
Study: 21615360
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection after medical treatment
Study: 19651921
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (perindopril-indapamide + intensive glucose control)
Study: 16337687
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light treatment for 8 weeks
Study: 16337687
Drug: Phase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase of sleep-wake rhythm assessed by daily sleep logs
Study: 15349005
Drug: Venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended-release (VXR)
Study: 115049
Drug: Ethanol 0.54
Normalized name: ethanol 0.547 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.54 g/kg
Study: 23827726
Drug: AZD1981 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 1000 mg twice daily
Study: 21691611
Drug: Titanium oxide-anodized
Normalized name: cobalt titanium oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium oxide-anodized (ADZ) implants
Study: 15526717
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin (I) levels in girls with obesity (OB)
Study: 15526717
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin (I) levels in non-obese (nOB) girls
Study: 15526717
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose (G) levels in girls with obesity (OB)
Study: 15526717
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose (G) levels in non-obese (nOB) girls
Study: 15526717
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) observed in girls with obesity (OB)
Study: 15526717
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) observed in non-obese (nOB) girls
Study: 11251136
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.25% bupivacaine
Study: 9210503
Drug: BT563 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (10 mg/day; days 0-12; n=39)
Study: 9210503
Drug: ATG (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (5 mg/kg/day; days 0-6; n=41)
Study: 7962884
Drug: Associative Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associative Therapy (AT; attention-control program)
Study: 25229735
Drug: FES-assisted walking
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES-assisted walking therapy
Study: 16513003
Drug: Levodopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (200 mg)
Study: 12845933
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (n = 9) performing a progressive cardiovascular graded exercise protocol and resistance training twice a week for 12 weeks
Study: 10949062
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone (rhGH) administered at doses 10-20 times higher than those used for replacement therapy
Study: 10949062
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral or enteral nutritional formulas
Study: 6483639
Drug: Phenyltoloxamine 60
Normalized name: magnesium salicylate-phenyltoloxamine 600 mg-25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenyltoloxamine 60 mg
Study: 6483639
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen 650 mg and phenyltoloxamine 60 mg
Study: 21570204
Drug: Continuous 7‐days‐a‐week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 7‐days‐a‐week pelvic irradiation (1.6 Gy daily for Group A, 1.8 Gy daily for Group B)
Study: 19617657
Drug: alpha-lipoic acid,
Normalized name: Liver Protect, Acetylcysteine,Alpha-Lipoic Acid,Milk Thistle and Selenium oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid, 600 mg . day(‐1), for 8 days
Study: 2654200
Drug: Desipramine 150
Normalized name: desipramine 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 150 mg daily
Study: 8082553
Drug: Amantadine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 300 mg daily
Study: 807698
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (4,000 IU daily for two months)
Study: 807698
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (single large oral dose)
Study: 27389174
Drug: Ofatumumab 500
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 500 mg plus fludarabine and cyclophosphamide (FC)
Study: 27389174
Drug: Ofatumumab 1000
Normalized name: ofatumumab 1000 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 1000 mg plus fludarabine and cyclophosphamide (FC)
Study: 27389174
Drug: Ofatumumab pharmacokinetics
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab pharmacokinetics
Study: 22221440
Drug: Single-dose montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose montelukast (4 or 5 mg)
Study: 17301298
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (including lithotripsy)
Study: 8067808
Drug: Mefloquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine alone (750 mg immediately, followed by 500 mg 6 h later)
Study: 8067808
Drug: Artesunate followed
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate followed by mefloquine (800 mg artesunate over 2 days, followed by 750 mg mefloquine)
Study: 2722726
Drug: Intravenous cefmetazole
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefmetazole
Study: 6393937
Drug: Intravenous cefoxitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefoxitin
Study: 30469158
Drug: local therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: local therapies
Study: 30469158
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of etoposide, doxorubicin and cisplatin (plus mitotane)
Study: 15309422
Drug: Abacor (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacor (25 g soy protein with soy fiber and phospholipids)
Study: 15309422
Drug: SuproSoy (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SuproSoy (25 g soy protein without soy fiber and phospholipids)
Study: 15309422
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 g milk protein)
Study: 8918079
Drug: IFN-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha (3 to 6 million units of recombinant IFN-alpha 2b or lymphoblastoid IFN-alpha, given 3 times weekly for 12 to 36 weeks)
Study: 8918079
Drug: IFN-alpha (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha (total dose above 215 MU)
Study: 8918079
Drug: IFN-alpha (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha (treatment for at least 24 weeks)
Study: 2226690
Drug: Antagonist muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonist muscle vibration
Study: 2226690
Drug: Shortening agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortening agonist muscle vibration
Study: 7087285
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of amino acids and glucose (39.5 g of amino acids and 200 g of glucose)
Study: 7087285
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (800 ml)
Study: 7087285
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of amino acids and glucose
Study: 29318862
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment after surgery (Control group)
Study: 22302014
Drug: Pregabalin (150‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150‐600 mg/day)
Study: 18271232
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment at Sanyinjiao (SP 6), Fenglong (ST 40), Yinlingquan (SP 9), once a day
Study: 18271232
Drug: Allopurinol, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol, oral administration, twice a day, 100 mg each time
Study: 18271232
Drug: Probenecid, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid, oral administration, twice daily, 0.25 g each time
Study: 12196359
Drug: Biweekly CHOP
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2), prednisolone 100 mg for 5 days every 2 weeks)
Study: 12196359
Drug: Dose-escalated CHOP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated CHOP (cyclophosphamide 1500 mg/m(2), doxorubicin 70 mg/m(2), vincristine 1.4 mg/m(2), prednisolone 100 mg for 5 days every 3 weeks)
Study: 9785072
Drug: Tramadol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (10 mg bolus)
Study: 9785072
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg bolus)
Study: 9209174
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 g/d)
Study: 6125156
Drug: Triazolam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 1.0 mg
Study: 6125156
Drug: Flunitrazepam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2.0 mg
Study: 31168657
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg subcutaneously monthly for 12 months, followed by denosumab 60 mg subcutaneously every 6 months for 24 months
Study: 28078741
Drug: Art brut
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Art brut therapy program called go beyond the schizophrenia (GBTS)
Study: 26611765
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, amoxicillin, and clarithromycin) for 10 days
Study: 26611765
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole, bismuth subcitrate potassium, tetracycline, and metronidazole) for 10 days
Study: 20642487
Drug: milnacipran 200
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: milnacipran 200 mg/day
Study: 20642487
Drug: milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: milnacipran 100 mg/day
Study: 15748230
Drug: Low-dose DX-9065a
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DX-9065a
Study: 15748230
Drug: High-dose DX-9065a
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DX-9065a
Study: 12572381
Drug: Kesuning Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kesuning Granule (KSNG) 8 g, three times a day
Study: 12572381
Drug: Jinbei Tankeqing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinbei Tankeqing Granule (JBTKQ) 7 g, three times a day
Study: 9892479
Drug: Captopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (ACE inhibitor) therapy administered 48 to 72 hours postoperatively in group B (103 patients)
Study: 709092
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cholesterol diet
Study: 709092
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg cholesterol diet
Study: 709092
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cholesterol diet (after 600 mg diet)
Study: 709092
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (3 g daily) added to 100 mg cholesterol diet
Study: 709092
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (3 g daily) added to 600 mg cholesterol diet
Study: 24893708
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atomoxetine
Study: 8848904
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral promethazine (10 mg) and transdermal scopolamine (1.5 mg)
Study: 8848904
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam (5‐15 mg)
Study: 8848904
Drug: Oral promethazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral promethazine (10 mg)
Study: 8848904
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral promethazine and transdermal scopolamine